Stada Expands In Ukraine With Biopharma Deal

Acquisition Of Prescription And Consumer Units To Close By Year End

Stada has struck a deal to acquire the prescription and consumer health businesses of Ukraine’s Biopharma, including local manufacturing operations and around 300 new staff. Biopharma will retain its blood plasma-based business.

Map_Ukraine
The deal allows Stada to expand in Ukraine • Source: Shutterstock

Stada has outlined plans to become a “major pharma player in Ukraine” by acquiring the prescription and consumer health businesses of local firm Biopharma, “one of the key pharmaceutical producers” in the country.

More from Deals

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By 

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By 

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By 

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By 

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By 

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By 

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By 

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.